EA202192122A1 - Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения - Google Patents
Соединения, обладающие активностью индуцирования ферроптоза, и способы их примененияInfo
- Publication number
- EA202192122A1 EA202192122A1 EA202192122A EA202192122A EA202192122A1 EA 202192122 A1 EA202192122 A1 EA 202192122A1 EA 202192122 A EA202192122 A EA 202192122A EA 202192122 A EA202192122 A EA 202192122A EA 202192122 A1 EA202192122 A1 EA 202192122A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- inducing activity
- ferroptose
- methods
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Настоящее изобретение относится к соединениям формулы (I), обладающим активностью индуцирования ферроптоза, к способу лечения субъекта, страдающего от рака, указанными соединениями и к комбинированному лечению в комбинации со вторым терапевтическим агентом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962893092P | 2019-08-28 | 2019-08-28 | |
PCT/US2020/020150 WO2020176757A1 (en) | 2019-02-27 | 2020-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192122A1 true EA202192122A1 (ru) | 2021-12-15 |
Family
ID=72238937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192122A EA202192122A1 (ru) | 2019-08-28 | 2020-02-27 | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3931183A1 (ru) |
JP (1) | JP2022522694A (ru) |
KR (1) | KR20220012221A (ru) |
CN (1) | CN114008024A (ru) |
AU (1) | AU2020228056A1 (ru) |
BR (1) | BR112021016833A2 (ru) |
CA (1) | CA3131385A1 (ru) |
EA (1) | EA202192122A1 (ru) |
IL (1) | IL285730A (ru) |
MX (1) | MX2021010173A (ru) |
SG (1) | SG11202109035QA (ru) |
TW (1) | TW202045480A (ru) |
WO (1) | WO2020176757A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
MX2020008906A (es) | 2018-02-28 | 2021-02-26 | Ferro Therapeutics Inc | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. |
US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
US20240092739A1 (en) * | 2020-08-26 | 2024-03-21 | Ferro Therapeutics, Inc | Compounds and methods of use |
KR20230110964A (ko) * | 2022-01-17 | 2023-07-25 | 포항공과대학교 산학협력단 | Marh6(marchf6) 조절제를 포함하는, 페로토시스 조절용 조성물 및 방법 |
CN114984019B (zh) * | 2022-07-15 | 2023-08-22 | 山东中医药大学 | 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用 |
WO2024015637A1 (en) * | 2022-07-15 | 2024-01-18 | Ferro Therapeutics, Inc. | Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer |
CN116983310B (zh) * | 2023-08-29 | 2024-04-30 | 南方医科大学南方医院 | 一种治疗肝癌的药物组合物及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038563A2 (en) * | 2000-11-08 | 2002-05-16 | Lilly Icos Llc | Condensed pyrazindione derivatives as pde inhibitors |
EP3791870A1 (en) * | 2013-12-02 | 2021-03-17 | The Trustees of Columbia University in the City of New York | Modulating ferroptosis and treating excitotoxic disorders |
WO2017035354A1 (en) * | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
US20190008961A1 (en) * | 2016-01-07 | 2019-01-10 | The Broad Institute, Inc. | Compounds and methods for increasing tumor infiltration by immune cells |
WO2018118711A1 (en) * | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
MX2020008906A (es) * | 2018-02-28 | 2021-02-26 | Ferro Therapeutics Inc | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. |
EP4076434A1 (en) * | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
CN113336748B (zh) * | 2021-04-12 | 2022-03-25 | 北京大学 | 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物 |
-
2020
- 2020-02-27 JP JP2021549973A patent/JP2022522694A/ja active Pending
- 2020-02-27 CN CN202080028989.0A patent/CN114008024A/zh active Pending
- 2020-02-27 BR BR112021016833A patent/BR112021016833A2/pt not_active Application Discontinuation
- 2020-02-27 MX MX2021010173A patent/MX2021010173A/es unknown
- 2020-02-27 EA EA202192122A patent/EA202192122A1/ru unknown
- 2020-02-27 EP EP20712811.7A patent/EP3931183A1/en active Pending
- 2020-02-27 KR KR1020217030619A patent/KR20220012221A/ko unknown
- 2020-02-27 TW TW109106570A patent/TW202045480A/zh unknown
- 2020-02-27 AU AU2020228056A patent/AU2020228056A1/en not_active Abandoned
- 2020-02-27 CA CA3131385A patent/CA3131385A1/en active Pending
- 2020-02-27 WO PCT/US2020/020150 patent/WO2020176757A1/en unknown
- 2020-02-27 SG SG11202109035QA patent/SG11202109035QA/en unknown
-
2021
- 2021-08-19 IL IL285730A patent/IL285730A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020228056A1 (en) | 2021-09-16 |
JP2022522694A (ja) | 2022-04-20 |
KR20220012221A (ko) | 2022-02-03 |
MX2021010173A (es) | 2021-12-10 |
TW202045480A (zh) | 2020-12-16 |
SG11202109035QA (en) | 2021-09-29 |
BR112021016833A2 (pt) | 2021-11-23 |
CN114008024A (zh) | 2022-02-01 |
EP3931183A1 (en) | 2022-01-05 |
WO2020176757A1 (en) | 2020-09-03 |
IL285730A (en) | 2021-10-31 |
CA3131385A1 (en) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
EA202091846A1 (ru) | Соединения с активностью, индуцирующей ферроптоз, и способы их применения | |
EA202190630A1 (ru) | Способы комбинированной терапии | |
JOP20210154B1 (ar) | مثبطات kif18a | |
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
MX2021007104A (es) | Inhibidores de kif18a. | |
EA201892510A2 (ru) | Комбинированная терапия для лечения рака | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
MX2022001181A (es) | Inhibidores de kif18a. | |
EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
EA201890878A1 (ru) | Способ лечения медуллобластомы с помощью ингибитора ezh2 | |
EA202091640A1 (ru) | Способы лечения опосредованного il-6 воспаления без иммунодепрессии | |
EA202193111A1 (ru) | Композиции и способы для лечения рака | |
EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
EA202192746A1 (ru) | Гетероциклические соединения и их применение | |
EA202092540A1 (ru) | Комбинации для лечения рака | |
EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи |